tranilast and Adenocarcinoma--Scirrhous

We examined the effect of Tranilast on the reduction of the administered dose of cisplatin using a scirrhous gastric cancer model. Scirrhous gastric cancer cell line, OCUM-2M, and gastric fibroblasts, NF-10, were used. The IC50 values of CDDP to OCUM-2M cells were decreased by Tranilast in vitro. The combination treatment with Tranilast and CDDP decreased the xenografted tumor size. The combination therapy decreased fibrosis and mitosis, and increased apoptosis. These findings suggest that Tranilast increased the CDDP response on scirrhous gastric cancer. The combination treatment with Tranilast and CDDP may be useful as a new therapy for scirrhous gastric carcinoma.

Topics: Adenocarcinoma, Scirrhous; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; ortho-Aminobenzoates; Stomach Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured